// App-Quantinova.ai

: NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC).

Researchers

Presenter

  • Mairead Geraldine McNamara

Principal Investigators

  • Zoe Craig

  • Rohini Sharma

  • Olusola Olusesan Faluyi

  • Jonathan Wadsley

  • Carys Morgan

  • Lucy R. Wall

  • Ian Chau

  • Nick Reed

  • Debashis Sarker

  • Jane Margetts

  • Daniel Krell

  • Judith Cave

  • Sothi Sharmila

  • Alan Anthoney

  • Alkesh Patel

  • Angela Lamarca

  • Richard Hubner

  • Juan W. Valle

Medical Centers

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Kings College London, London, United Kingdom

  • Weston Park Cancer Centre, Sheffield, United Kingdom

  • Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom

  • University of Manchester and The Christie NHS FT, Manchester, United Kingdom

  • Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom

  • Clatterbridge Cancer Centre, Merseyside, United Kingdom

  • Velindre Cancer Centre, Cardiff, United Kingdom

  • Mount Vernon Cancer Centre, Middlesex, United Kingdom

  • Newcastle Hospital NHS Foundation Trust, Newcastle, United Kingdom

  • The Beatson, Glasgow, United Kingdom

  • Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, United Kingdom

  • University of Southampton, Southampten, United Kingdom

  • Fundacion Jimenez Diaz University Hospital, Las Rozas, Alava, Spain

  • University Hospital, Coventry, United Kingdom

  • Imperial College, London, United Kingdom

  • The Royal Marsden Hospital, London, United Kingdom

  • Western General Hospital, Edinburgh, United Kingdom

Locations

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • High-grade extrapulmonary neuroendocrine carcinoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Irinotecan

  • Adrucil injection

  • Fluorouracil

  • L-leucovorin

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Superiority

  • Multicenteric

Phase

  • II

Study Id's

  • NCT03837977

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved